Special Issue

Multiple Biomarkers for the Diagnosis and Precision Treatment of Depression

Message from the Guest Editor

As defined by the FDA and NIH, a biomarker is "a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes or responses to an exposure or intervention". Biomarkers have been used and continue to be used widely in almost all branches of medicine, but their use in psychiatry has lagged. Frequently, psychiatric disorders coexist either with another primary psychiatric diagnosis or as comorbid diagnoses with medical conditions. Despite that, the discovery of potential biomarkers linked to a psychiatric condition and/or to a specific symptom within a certain syndrome has shown truly impressive findings over the past few decades. In this Special Issue, we will focus on those biomarkers that have been extensively investigated and have been shown to possess validity, sensitivity, and reproducibility both as diagnostic biomarkers but also as monitoring biomarkers indicative of treatment response and overall outcome. I believe we have an array of such candidate biomarkers subdivided into the following categories: molecular, physiologic, radiographic, genomic, and pharmacogenomic biomarkers.

Guest Editor

Prof. Dr. Angelos Halaris

Department of Psychiatry, Loyola University Stritch School of Medicine, Maywood, IL 60153, USA

Deadline for manuscript submissions

15 December 2024

Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed

mdpi.com/journal/
jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

MDPI